1.Silencing CD46 and DSG2 in host A549 cells inhibits entry of human adenovirus type 3 and type 7 and reduces interleukin-8 release.
Zhong Ying YANG ; Yang Xi FU ; Luo REN ; Shi Yi CHEN ; En Mei LIU ; Na ZANG
Journal of Southern Medical University 2022;42(9):1344-1350
OBJECTIVE:
To investigate the effect of silencing CD46 and desmoglein 2 (DSG2) in host A549 cells on the entry of human adenovirus type 3 (HAdV-3) and type 7 (HAdV-7) and host cell secretion of inflammatory cytokines.
METHODS:
RNA interference technique was use to silence the expression of CD46 or DSG2 in human epithelial alveolar A549 cells as the host cells of HAdV-3 or HAdV-7. The binding of the viruses with CD46 and DSG2 were observed with immunofluorescence staining at 0.5 and 1 h after viral infection. The viral load in the host cells was determined with qRT-PCR, and IL-8 secretion level was measured using ELISA.
RESULTS:
In infected A549 cells, immunofluorescent staining revealed colocalization of HAdV-3 and HAdV-37 with their receptors CD46 and DSG2 at 0.5 h and 2 h after infection, and the copy number of the viruses increased progressively after the infection in a time-dependent manner. In A549 cells with CD46 silencing, the virus titers were significantly lower at 2, 6, 12 and 24 h postinfection in comparison with the cells without gene silencing; the virus titers were also significantly decreased in the cells with DSG2 silencing. The secretion level of IL-8 increased significantly in A549 cells without siRNA transfection following infection with HAdV-3 and HAdV-7 (P < 0.0001), but decreased significantly in cells with CD46 and DSG2 silencing (P < 0.0001).
CONCLUSION
HAdV-3 and HAdV-7 enter host cells by binding to their receptors CD46 and DSG2, and virus titer and cytokines release increase with infection time. Silencing CD46 and DSG2 can inhibit virus entry and cytokine IL-8 production in host cells.
A549 Cells
;
Adenoviruses, Human/metabolism*
;
Desmoglein 2/metabolism*
;
Humans
;
Interleukin-8
;
Membrane Cofactor Protein/genetics*
;
RNA, Small Interfering
2.Inhibitive effects of chimeric oncolytic adenovirus SG235 on leukemia cells in vitro.
Chun-mei YANG ; Hui LIU ; Xiu-di YANG ; Jie JIN ; Wen-bin QIAN
Journal of Zhejiang University. Medical sciences 2010;39(3):226-230
OBJECTIVETo investigate the inhibitive effects of chimeric oncolytic adenovirus SG235 on leukemia cells in vitro.
METHODSThe ability of SG235 to infect leukemia cells and the expression of CD46 on blasts from the patient with leukemia were detected by flow cytometry (FACS). The cytotoxicity of the virus was evaluated by MTT assay. Apoptosis induced by SG235 was detected with Annexin-V/PI staining and TUNEL assay followed by FACS analysis.
RESULTThe majority of leukemia cells from the patient with acute leukemia was CD46-positive. GFP-positive cells were 45.1%, 35.7%, 54.2%, 37.0%, 30.1%, %67.1, 17.2% and 33.1% in Mutz-1, Kasumi-1, K562, HL60, Molt- 4, RPMI8226, L428, and Jurkat cell lines treated with SG235-EGFP vector at MOI (multiplicity of infection) of 50 for 48 h.SG235 treatment resulted in marked growth inhibition and apoptosis of Kassumi-1 cells, and also significantly inhibited expression of p-Akt.
CONCLUSIONThe chimeric oncolytic adenovirus SG235 can infect leukemia cell effectively and results in the growth inhibition and apoptosis of Kasumi-1 cells in vitro.
Adenoviridae ; genetics ; Apoptosis ; Cell Line, Tumor ; Cell Proliferation ; Genetic Vectors ; Humans ; Leukemia ; genetics ; metabolism ; pathology ; Membrane Cofactor Protein ; metabolism ; Oncolytic Viruses ; Transfection
3.Co-expression and synergic effect of human complement regulatory proteins DAF and MCP.
Li XU ; Zhouzhou ZHAO ; Hui LIU ; Dahe JIANG ; Wenxin LI
Chinese Journal of Biotechnology 2008;24(2):220-225
Recombinant expression vector pcDNA3-DAFMCP-DP containing human membrane complement regulatory proteins (hCRPs) decay accelerating factor (DAF) and membrane cofactor protein (MCP) cDNA was constructed by using two independent promoters. After transfected into NIH3T3 cells by calcium phosphate-DNA precipitate method, NIH3T3 pcDNA3-DAFMCP-DP transfectants were obtained by G418 selection. Extraneous genes integration was identified by PCR. The co-expression of human DAF and MCP at both mRNA and protein levels was confirmed by using RT-PCR and Western blot analysis. Human DAF and MCP cDNA were integrated into NIH3T3 pcDNA3-DAFMCP-DP genomic DNA after continuous 30 times passages, indicating that NIH3T3 pcDNA3-DAFMCP-DP were stable cell lines. Human C-mediated cytolysis assays showed that NIH3T3 cells transfected stably with pcDNA3-DAF, pcDNA3-MCP, and pcDNA3-DAFMCP-DP were protected from C-mediated damage and co-expressed human DAF and MCP provided more excellent protection against C-mediated attack, which was compared with either DAF or MCP alone. These results suggest that the dicistronic vector could improve the efficiency of multi-gene delivery and benefit the synergic effect of human membrane complement regulatory proteins DAF and MCP.
3T3 Cells
;
Animals
;
CD55 Antigens
;
biosynthesis
;
genetics
;
pharmacology
;
DNA, Complementary
;
genetics
;
Drug Synergism
;
Graft Rejection
;
prevention & control
;
Humans
;
Membrane Cofactor Protein
;
biosynthesis
;
genetics
;
pharmacology
;
Mice
;
Recombinant Fusion Proteins
;
biosynthesis
;
genetics
;
pharmacology
;
Transfection
4.CD36 gene deletion reduces muscle insulin sensitivity in mice by up-regulating PTP1B expression.
Lin CHEN ; Han ZENG ; Hong QIN ; Xiong Zhong RUAN ; Ping YANG
Journal of Southern Medical University 2022;42(3):392-398
OBJECTIVE:
To investigate the effect CD36 deficiency on muscle insulin signaling in mice fed a normal-fat diet and explore the possible mechanism.
METHODS:
Wild-type (WT) mice and systemic CD36 knockout (CD36-/-) mice with normal feeding for 14 weeks (n=12) were subjected to insulin tolerance test (ITT) after intraperitoneal injection with insulin (1 U/kg). Real-time PCR was used to detect the mRNA expressions of insulin receptor (IR), insulin receptor substrate 1/2 (IRS1/2) and protein tyrosine phosphatase 1B (PTP1B), and Western blotting was performed to detect the protein expressions of AKT, IR, IRS1/2 and PTP1B in the muscle tissues of the mice. Tyrosine phosphorylation of IR and IRS1 and histone acetylation of PTP1B promoter in muscle tissues were detected using co-immunoprecipitation (Co-IP) and chromatin immunoprecipitation (ChIP), respectively.
RESULTS:
CD36-/- mice showed significantly lowered insulin sensitivity with obviously decreased area under the insulin tolerance curve in comparison with the WT mice (P < 0.05). CD36-/- mice also had significantly higher serum insulin concentration and HOMA-IR than WT mice (P < 0.05). Western blotting showed that the p-AKT/AKT ratio in the muscle tissues was significantly decreased in CD36-/- mice as compared with the WT mice (P < 0.01). No significant differences were found in mRNA and protein levels of IR, IRS1 and IRS2 in the muscle tissues between WT and CD36-/- mice (P>0.05). In the muscle tissue of CD36-/- mice, tyrosine phosphorylation levels of IR and IRS1 were significantly decreased (P < 0.05), and the mRNA and protein levels of PTP1B (P < 0.05) and histone acetylation level of PTP1B promoters (P < 0.01) were significantly increased as compared with those in the WT mice. Intraperitoneal injection of claramine, a PTP1B inhibitor, effectively improved the impairment of insulin sensitivity in CD36-/- mice.
CONCLUSION
CD36 is essential for maintaining muscle insulin sensitivity under physiological conditions, and CD36 gene deletion in mice causes impaired insulin sensitivity by up-regulating muscle PTP1B expression, which results in detyrosine phosphorylation of IR and IRS1.
Animals
;
Gene Deletion
;
Histones/genetics*
;
Insulin
;
Insulin Receptor Substrate Proteins/metabolism*
;
Insulin Resistance/genetics*
;
Membrane Cofactor Protein/genetics*
;
Mice
;
Mice, Knockout
;
Muscles/metabolism*
;
Phosphoric Monoester Hydrolases/metabolism*
;
Protein Tyrosine Phosphatase, Non-Receptor Type 1/metabolism*
;
Proto-Oncogene Proteins c-akt/metabolism*
;
RNA, Messenger/metabolism*
;
Receptor, Insulin/metabolism*
;
Tyrosine/genetics*
;
Up-Regulation